Responses

Download PDFPDF

Trans-Tenon’s retrobulbar triamcinolone infusion for the treatment of uveitis
Free
Compose Response

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Statement of Competing Interests

PLEASE NOTE:

  • Responses are moderated before posting and publication is at the absolute discretion of BMJ, however they are not peer-reviewed
  • Once published, you will not have the right to remove or edit your response. Removal or editing of responses is at BMJ's absolute discretion
  • If patients could recognise themselves, or anyone else could recognise a patient from your description, please obtain the patient's written consent to publication and send them to the editorial office before submitting your response [Patient consent forms]
  • By submitting this response you are agreeing to our full [Response terms and requirements]

Vertical Tabs

Other responses

Jump to comment:

  • Published on:
    Treatment for presumed Ocular tuberculosis

    Dear Editor

    I was delighted to read Dr Okada’s reply to my letter.[1] At the risk of transgressing from the point of the original article [2] that dealt with a novel technique to administer triamcinolone to a wide group of patients with uveitis, I would like to reply:

    1. The WHO guidelines are indeed silent on the treatment of latent tuberculosis which can be defined as merely positive mantoux tests w...

    Show More
    Conflict of Interest:
    None declared.
  • Published on:
    Much Ado About Periocular Corticosteroids

    Dear Editor

    I thank Dr Okada et al for replying to my letter to the editor regarding their article "Trans-Tenon's retrobulbar triamcinolone infusion for the treatment of uveitis".[1] While speculating that the cause of the lack of therapeutic response to sub-tenon’s corticosteroids may be because of placement at a site relatively far from the target zone, I had quoted only the article by Freeman et al...

    Show More
    Conflict of Interest:
    None declared.
  • Published on:
    Trans-Tenon's retrobulbar triamcinolone infusions in uveitis
    • Annabelle A Okada, Associate Professor of Ophthalmology
    • Other Contributors:
      • Toshiko Wakabayashi

    Dear Editor

    We appreciate the interest and many comments we have received regarding our recent article on "Trans-Tenon's retrobulbar triamcinolone infusion for the treatment of uveitis."[1]

    In reply to the comments by Dr Vedantham, we acknowledge the paucity of experimental data to actually prove that accurate placement of corticosteroids into the sub-Tenon's space provides good drug penetration into the ey...

    Show More
    Conflict of Interest:
    None declared.
  • Published on:
    Comments on periocular corticosteroid therapy

    Dear Editor

    I read with great interest the article by Okada et al,[1] reporting the efficacy and complications of trans-tenon’s retrobulbar infusion of triamcinolone acetonide for posterior uveitic inflammation. The authors have to be commended for the excellent description of this novel technique.

    The efficacy of various modalities of corticosteroid injection has always been a matter of debate w...

    Show More
    Conflict of Interest:
    None declared.
  • Published on:
    Trans-Tenons Triamcinolone and Pretreatment

    Dear Editor

    I read with great interest the article by Okada et al.[1] I would like to make the following comments:
    (1) The authors describe three patients of tubercular uveitis who are being treated with isoniazid and rifampicin for a month prior to their treatment with trans-tenons triamcinolone. However, current WHO guidelines recommend an initial phase of 2 months with four drugs (iso...

    Show More
    Conflict of Interest:
    None declared.